Whether to target single or multiple CDKs for therapy? That is the question

Journal of Cellular Physiology

Volumn 226, Issue 2, 2011, Pages 341-349

  Wesierska Gadek, Józefa ^a   Maurer, Margarita ^a   Zulehner, Nora ^a   Komina, Oxana ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; AT 7519; ATM PROTEIN; BORTEZOMIB; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; DEXAMETHASONE; FLAVOPIRIDOL; GEMCITABINE; LETROZOLE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; OLOMOUCINE; P 276 00; PHA 848125; PROTEIN P53; R 547; RGB 286638; ROSCOVITINE; SCH 727965; UNCLASSIFIED DRUG; ZK 304709;

BREAST CANCER; CANCER CELL; CELL CYCLE; CELL STRESS; CLINICAL TRIAL; CYTOSTASIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVATION; HUMAN; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NASOPHARYNX CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHABDOMYOSARCOMA; TRANSCRIPTION REGULATION;

CELL CYCLE; CLINICAL TRIALS AS TOPIC; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME ACTIVATION; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN SUBUNITS; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA;

EID: 78649658736     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22426     Document Type: Review

References (128)

1. Bartova I, Otyepka M, Kriz Z, Koca J. 2004. Activation and inhibition of cyclin-dependent kinase-2 by phosphorylation; a molecular dynamics study reveals the functional importance of the glycine-rich loop. Protein Sci 13: 1449-1457.
2. Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S. 2006. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 66: 7661-7667.
3. Besson A, Dowdy SF, Roberts JM. 2008. CDK inhibitors: Cell cycle regulators and beyond. Dev Cell 14: 159-169.
4. Bockstaele L, Bisteau X, Paternot S, Roger PP. 2009. Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation. Mol Cell Biol 29: 4188-4200.
5. Brambilla R, Draetta G. 1994. Molecular cloning of PISSLRE, a novel putative member of the cdk family of protein serine/threonine kinases. Oncogene 9: 3037-3041.
6. Bres V, Yoh SM, Jones KA. 2008. The multi-tasking P-TEFb complex. Curr Opin Cell Biol 20: 334-340.
7. Bunnell BA, Heath LS, Adams DE, Lahti JM, Kidd VJ. 1990. Increased expression of a 58-kDa protein kinase leads to changes in the CHO cell cycle. Proc Natl Acad Sci USA 87: 7467-7471.
8. Chen HH, Wang YC, Fann MJ. 2006. Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation. Mol Cell Biol 26: 2736-2745.
9. Chen HH, Wong YH, Geneviere AM, Fann MJ. 2007. CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing. Biochem Biophys Res Commun 354: 735-740.
10. Chu IM, Hengst L, Slingerland JM. 2008. The Cdk inhibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8: 253-267.
11. Clarke DJ, Diaz-Martinez LA, Gimenez-Abian JF. 2005. Anaphase promoting complex or cyclosome? Cell Cycle 4: 1585-1592.
12. Core LJ, Lis JT. 2008. Transcription regulation through promoter-proximal pausing of RNA polymerase II. Science 319: 1791-1792.
13. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. 1997. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243: 518-526.
14. de Graaf K, Hekerman P, Spelten O, Herrmann A, Packman LC, Bussow K, Muller-Newen G, Becker W. 2004. Characterization of cyclin L2, a novel cyclin with an arginine/serine-rich domain: Phosphorylation by DYRK1A and colocalization with splicing factors. J Biol Chem 279: 4612-4624.
15. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. 1979. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 76: 2420-2424.
16. Desai D, We{ogonek}ssling HC, Fisher RP, Morgan DO. 1995. Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2. Mol Cell Biol 15: 345-350.
17. Devault A, Martinez AM, Fesquet D, Labbe JC, Morin N, Tassan JP, Nigg EA, Cavadore JC, Doree M. 1995. MAT1 ('menage a trois') a new RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish and Xenopus CAK. EMBO J 14: 5027-5036.
18. Dey A, Wong ET, Cheok CF, Tergaonkar V, Lane DP. 2008. R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: Implications in cancer therapy. Cell Death Differ 15: 263-273.
19. Dhavan R, Greer PL, Morabito MA, Orlando LR, Tsai LH. 2002. The cyclin-dependent kinase 5 activators p35 and p39 interact with the alpha-subunit of Ca2+/calmodulin-dependent protein kinase II and alpha-actinin-1 in a calcium-dependent manner. J Neurosci 22: 7879-7891.
20. Easton J, Wei T, Lahti JM, Kidd VJ. 1998. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. Cancer Res 58: 2624-2632.
21. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
22. Fesquet D, Labbe JC, Derancourt J, Capony JP, Galas S, Girard F, Lorca T, Shuttleworth J, Doree M, Cavadore JC. 1993. The MO15 gene encodes the catalytic subunit of a protein kinase that activates cdc2 and other cyclin-dependent kinases (CDKs) through phosphorylation of Thr161 and its homologues. EMBO J 12: 3111-3121.
23. Fisher RP. 2005. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 118 (Pt 22): 5171-5180.
24. Fisher RP, Morgan DO. 1994. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 78: 713-724.
25. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL. 2004. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3: 1427-1438.
26. Galons H, Oumata N, Meijer L. 2010. Cyclin-dependent kinase inhibitors: A survey of recent patent literature. Expert Opin Ther Pat 20: 377-404.
27. Gautier J, Solomon MJ, Booher RN, Bazan JF, Kirschner MW. 1991. cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 67: 197-211.
28. Gonzalez S, Klatt P, Delgado S, Conde E, Lopez-Rios F, Sanchez-Cespedes M, Mendez J, Antequera F, Serrano M. 2006. Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 440: 702-706.
29. Grana X, Claudio PP, De Luca A, Sang N, Giordano A. 1994. PISSLRE, a human novel CDC2-related protein kinase. Oncogene 9: 2097-2103.
30. Hannon GJ, Casso D, Beach D. 1994. KAP: A dual specificity phosphatase that interacts with cyclin-dependent kinases. Proc Natl Acad Sci USA 91: 1731-1735.
31. Havlicek L, Hanus J, Vesely J, Leclerc S, Meijer L, Shaw G, Strnad M. 1997. Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem 40: 408-412.
32. Hsieh WS, Soo R, Peh BK, Loh T, Dong D, Soh D, Wong LS, Green S, Chiao J, Cui CY, Lai YF, Lee SC, Mow B, Soong R, Salto-Tellez M, Goh BC. 2009. Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin Cancer Res 15: 1435-1442.
33. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, Pavletich NP. 1995. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376: 313-320.
34. Jorda EG, Verdaguer E, Canudas AM, Jimenez A, Bruna A, Caelles C, Bravo R, Escubedo E, Pubill D, Camarasa J, Pallas M, Camins A. 2003. Neuroprotective action of flavopiridol, a cyclin-dependent kinase inhibitor, in colchicine-induced apoptosis. Neuropharmacology 45: 672-683.
35. Kasten M, Giordano A. 2001. Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity. Oncogene 20: 1832-1838.
36. Kim YJ, Bjorklund S, Li Y, Sayre MH, Kornberg RD. 1994. A multiprotein mediator of transcriptional activation and its interaction with the C-terminal repeat domain of RNA polymerase II. Cell 77: 599-608.
37. Ko J, Humbert S, Bronson RT, Takahashi S, Kulkarni AB, Li E, Tsai LH. 2001a. p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neurosci 21: 6758-6771.
38. Ko TK, Kelly E, Pines J. 2001b. CrkRS: A novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles. J Cell Sci 114 (Pt 14): 2591-2603.
39. Ko MT, Su CY, Huang SC, Chen CH, Hwang CF. 2009. Overexpression of cyclin E messenger ribonucleic acid in nasopharyngeal carcinoma correlates with poor prognosis. J Laryngol Otol 123: 1021-1026.
40. Koumenis C, Giaccia A. 1997. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol 17: 7306-7316.
41. Krek W, Nigg EA. 1991. Differential phosphorylation of vertebrate p34cdc2 kinase at the G1/S and G2/M transitions of the cell cycle: Identification of major phosphorylation sites. EMBO J 10: 305-316.
42. Krystof V, Chamrad I, Jorda R, Kohoutek J. 2010. Pharmacological targeting of CDK9 in cardiac hypertrophy. Med Res Rev 30: 646-666.
43. Lahti JM, Xiang J, Heath LS, Campana D, Kidd VJ. 1995. PITSLRE protein kinase activity is associated with apoptosis. Mol Cell Biol 15: 1-11.
44. Lane DP. 1992. Cancer. p53, guardian of the genome. Nature 358: 15-16.
45. Lane DP, Crawford LV. 1979. T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263.
46. Lapenna S, Giordano A. 2009. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8: 547-566.
47. Larochelle S, Chen J, Knights R, Pandur J, Morcillo P, Erdjument-Bromage H, Tempst P, Suter B, Fisher RP. 2001. T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity. EMBO J 20: 3749-3759.
48. Larochelle S, Merrick KA, Terret ME, Wohlbold L, Barboza NM, Zhang C, Shokat KM, Jallepalli PV, Fisher RP. 2007. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell 25: 839-850.
49. Lew J, Huang QQ, Qi Z, Winkfein RJ, Aebersold R, Hunt T, Wang JH. 1994. A brain-specific activator of cyclin-dependent kinase 5. Nature 371: 423-426.
50. Li T, Inoue A, Lahti JM, Kidd VJ. 2004. Failure to proliferate and mitotic arrest of CDK11(p110/p58)-null mutant mice at the blastocyst stage of embryonic cell development. Mol Cell Biol 24: 3188-3197.
51. Linzer DI, Levine AJ. 1979. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-52.
52. Lopes JP, Oliveira CR, Agostinho P. 2007. Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: Implications for Alzheimer's disease and prion-related encephalopathies. Cell Mol Neurobiol 27: 943-957.
53. Ma Y, Cress WD, Haura EB. 2003. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther 2: 73-81.
54. Malumbres M, Barbacid M. 2001. To cycle or not to cycle: A critical decision in cancer. Nat Rev Cancer 1 222-231.
55. Malumbres M, Barbacid M. 2005. Mammalian cyclin-dependent kinases. Trends Biochem Sci 30: 630-641.
56. Malumbres M, Barbacid M. 2009. Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 9: 153-166.
57. Marshall RM, Grana X. 2006. Mechanisms controlling CDK9 activity. Front Biosci 11: 2598-2613.
58. Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E, Nowell P, Deprimo SE, Sadis S, Eck S, Schuster SJ, Diehl JA, Wasik MA. 2006. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 108: 1744-1750.
59. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP. 1997. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243: 527-536.
60. Meyerson M, Enders GH, Wu CL, Su LK, Gorka C, Nelson C, Harlow E, Tsai LH. 1992. A family of human cdc2-related protein kinases. EMBO J 11: 2909-2917.
61. Morgan DO. 1995. Principles of CDK regulation. Nature 374: 131-134.
62. Morgan DO. 1997. Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13: 261-291.
63. Nakayama KI, Nakayama K. 2006. Ubiquitin ligases: Cell-cycle control and cancer. Nat Rev Cancer 6: 369-381.
64. Nigg EA. 1993. Cellular substrates of p34(cdc2) and its companion cyclin-dependent kinases. Trends Cell Biol 3: 296-301.
65. Norbury C, Nurse P. 1992. Animal cell cycles and their control. Annu Rev Biochem 61: 441-470.
66. Nyberg KA, Michelson RJ, Putnam CW, Weinert TA. 2002. Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 36: 617-656.
67. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, Tognin S, Marchisio PC, Altieri DC. 2000. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 97: 13103-13107.
68. O'Connor DS, Wall NR, Porter AC, Altieri DC. 2002. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2: 43-54.
69. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. 2000. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849-862.
70. O'Dwyer PJ, LoRusso P, DeMichele A. 2007. A Phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991. Presented at 2007 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2007.
71. Ohshima T, Ward JM, Huh CG, Longenecker G, Veeranna Pant HC, Brady RO, Martin LJ, Kulkarni AB. 1996. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA 93: 11173-11178.
72. Ortega S, Malumbres M, Barbacid M. 2002. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602: 73-87.
73. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. 1995. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685.
74. Palancade B, Bensaude O. 2003. Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation. Eur J Biochem 270: 3859-3870.
75. Parker LL, Piwnica-Worms H. 1992. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 257: 1955-1957.
76. Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH. 1998. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J Biol Chem 273: 24057-24064.
77. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. 1999. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402: 615-622.
78. Perdiguero E, Nebreda AR. 2004. Regulation of Cdc25C activity during the meiotic G2/M transition. Cell Cycle 3: 733-737.
79. Pierga J, Faivre S, Vera K. 2003. A phase I and pharmacokonetik (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients with advanced malignancy. Proc Am Soc Clin Oncol 22: 840.
80. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. 1994. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-566.
81. Poon RY, Hunter T. 1995. Dephosphorylation of Cdk2 Thr160 by the cyclin-dependent kinase-interacting phosphatase KAP in the absence of cyclin. Science 270: 90-93.
82. Reinhardt HC, Yaffe MB. 2009. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 21: 245-255.
83. Rizzolio F, Tuccinardi T, Caligiuri I, Lucchetti C, Giordano A. 2010. CDK inhibitors: From the bench to clinical trials. Curr Drug Targets 11: 279-290.
84. Rogalinska M, Blonski JZ, Komina O, Goralski P, Zolnierczyk JD, Piekarski H, Robak T, Kilianska ZM, We{ogonek}sierska-Ga{ogonek}dek J. 2010. R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis. J Cell Biochem 109: 217-235.
85. Rossi DJ, Londesborough A, Korsisaari N, Pihlak A, Lehtonen E, Henkemeyer M, Makela TP. 2001. Inability to enter S phase and defective RNA polymerase II CTD phosphorylation in mice lacking Mat1. EMBO J 20: 2844-2856.
86. Russo AA, Jeffrey PD, Pavletich NP. 1996. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol 3: 696-700.
87. Saab R, Bills JL, Miceli AP, Anderson CM, Khoury JD, Fry DW, Navid F, Houghton PJ, Skapek SX. 2006. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther 5: 1299-1308.
88. Sano M, Schneider MD. 2003. Cyclins that don't cycle-cyclin T/cyclin-dependent kinase-9 determines cardiac muscle cell size. Cell Cycle 2: 99-104.
89. Sano M, Abdellatif M, Oh H, Xie M, Bagella L, Giordano A, Michael LH, DeMayo FJ, Schneider MD. 2002. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nat Med 8: 1310-1317.
90. Sano M, Wang SC, Shirai M, Scaglia F, Xie M, Sakai S, Tanaka T, Kulkarni PA, Barger PM, Youker KA, Taffet GE, Hamamori Y, Michael LH, Craigen WJ, Schneider MD. 2004. Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. EMBO J 23: 3559-3569.
91. Satyanarayana A, Kaldis P. 2009. Mammalian cell-cycle regulation: Several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 28: 2925-2939.
92. Schang LM, Coccaro E, Lacasse JJ. 2005. Cdk inhibitory nucleoside analogs prevent transcription from viral genomes. Nucleosides Nucleotides Nucleic Acids 24: 829-837.
93. Sedlacek HH. 2001. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 38: 139-170.
94. Senderowicz AM. 2003. Small-molecule cyclin-dependent kinase modulators. Oncogene 22: 6609-6620.
95. Serrano M, Hannon GJ, Beach D. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
96. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. 1997. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 11: 1464-1478.
97. Sherr CJ, Roberts JM. 1995. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163.
98. Sherr CJ, Roberts JM. 1999. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512.
99. Siegel-Lakhai WS, Rodenstein DO, Beijnen JH. 2005. Phase I stundy of seliciclib (CYC202 or P-roscovitine) in combination with gemcitabine (gem) / cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC). Presented at: ASCO Annual Meeting Orlando, FL, USA, 13-17, May 2005.
100. Smalley KS, Contractor R, Nguyen TK, Xiao M, Edwards R, Muthusamy V, King AJ, Flaherty KT, Bosenberg M, Herlyn M, Nathanson KL. 2008. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res 68: 5743-5752.
101. Smits VA, Medema RH. 2001. Checking out the G(2)/M transition. Biochim Biophys Acta 1519: 1-12.
102. Solomon MJ, Harper JW, Shuttleworth J. 1993. CAK, the p34cdc2 activating kinase, contains a protein identical or closely related to p40MO15. EMBO J 12: 3133-3142.
103. Song Z, Yao X, Wu M. 2003. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem 278: 23130-23140.
104. Sullivan M, Morgan DO. 2007. Finishing mitosis, one step at a time. Nat Rev Mol Cell Biol 8: 894-903.
105. Taylor WR, Stark GR. 2001. Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815.
106. Toyoshima H, Hunter T. 1994. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74.
107. Tsai LH, Delalle I, Caviness VS, Jr., Chae T, Harlow E. 1994. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371: 419-423.
108. Vazquez A, Bond EE, Levine AJ, Bond GL. 2008. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7: 979-987.
109. Vervoorts J, Luscher B. 2008. Post-translational regulation of the tumor suppressor p27(KIP1). Cell Mol Life Sci 65: 3255-3264.
110. Vlach J, Hennecke S, Amati B. 1997. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 16: 5334-5344.
111. Waga S, Hannon GJ, Beach D, Stillman B. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578.
112. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. 2003. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 63: 230-235.
113. Waltersson MA, Askmalm MS, Nordenskjold B, Fornander T, Skoog L, Stal O. 2009. Altered expression of cyclin E and the retinoblastoma protein influences the effect of adjuvant therapy in breast cancer. Int J Oncol 34: 441-448.
114. Wang S, Fischer PM. 2008. Cyclin-dependent kinase 9: A key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 29: 302-313.
115. Weinberg RA. 1995. The retinoblastoma protein and cell cycle control. Cell 81: 323-330.
116. Weinberg RA. 1996. The molecular basis of carcinogenesis: Understanding the cell cycle clock. Cytokines Mol Ther 2: 105-110.
117. Weingrill E, Wolfler A, Strunk D, Linkesch W, Sill H, Liebmann PM. 2007. Roscovitine in B-chronic lymphocytic leukemia cells: High apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status. Haematologica 92: 1286-1288.
118. We{ogonek}sierska-Ga{ogonek}dek J, Schmid G. 2006. Dual action of the inhibitors of cyclin-dependent kinases: Targeting of the cell-cycle progression and activation of wild-type p53 protein. Expert Opin Investig Drugs 15: 23-38.
119. We{ogonek}sierska-Ga{ogonek}dek J, Schmid G. 2007. Transcriptional repression of anti-apoptotic proteins mediated by the tumor suppressor protein p53. Cancer Ther 5: 203-212.
120. We{ogonek}sierska-Ga{ogonek}dek J, Gueorguieva M, Horky M. 2005. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol Cancer Ther 4: 113-124.
121. We{ogonek}sierska-Ga{ogonek}dek J, Schmitz ML, Ranftler C. 2007. Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells. J Cell Biochem 100: 865-874.
122. We{ogonek}sierska-Ga{ogonek}dek J, Wandl S, Kramer MP, Pickem C, Krystof V, Hajek SB. 2008. Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells. J Cell Biochem 105: 1161-1171.
123. We{ogonek}sierska-Ga{ogonek}dek J, Borza A, Komina O, Maurer M. 2009a. Impact of roscovitine, a selective CDK inhibitor, on cancer cells: Bi-functionality increases its therapeutic potential. Acta Biochim Pol 56: 495-501.
124. We{ogonek}sierska-Ga{ogonek}dek J, Borza A, Walzi E, Krystof V, Maurer M, Komina O, Wandl S. 2009b. Outcome of treatment of human HeLa cervical cancer cells with roscovitine strongly depends on the dosage and cell cycle status prior to the treatment. J Cell Biochem 106: 937-955.
125. We{ogonek}sierska-Ga{ogonek}dek J, Chamrád I, Kryštof V. 2009c. Novel potent pharmacological cyclin-dependent kinase inhibitors. Future Med Chem 1: 1561-1581.
126. Whittaker SR, Te Poele RH, Chan F, Linardopoulos S, Walton MI, Garrett MD, Workman P. 2007. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Cell Cycle 6: 3114-3131.
127. Wojciechowski J, Horky M, Gueorguieva M, We{ogonek}sierska-Ga{ogonek}dek J. 2003. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer 106: 486-495.
128. Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y, Gardner H, Kiyokawa H, Harris LN, Stal O, Sicinski P. 2006. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9: 23-32.